BASILEA PHARMACEUTICA AG ALLSCHWIL CHF1 (REGD) revenue breakdown overview

BASILEA PHARMACEUTICA AG ALLSCHWIL CHF1 (REGD) revenue for the last year amounted to 157.60 M CHF, the most of which — 157.63 M CHF — came from its highest performing source at the moment, Innovative Pharmaceutical Products, the year earlier bringing 147.76 M CHF. The greatest contribution to the revenue figure was made by Ireland — last year it brought BASILEA PHARMACEUTICA AG ALLSCHWIL CHF1 (REGD) 68.70 M CHF, and the year before that — 41.30 M CHF.